Sinovac Vaccines; DPR Legislator Addresses Its Low Efficacy

Translator:

Editor:

Petir Garda Bhwana

  • Font:
  • Ukuran Font: - +
  • A vaccinator officer shows the COVID-19 vaccine produced by Sinovac which will be injected to a number of representatives of officials during the second phase of vaccination at the Bandar Lampung City Government Office, Lampung, Friday, January 29, 2021. The second stage of vaccination in Bandar Lampung is targeted at 9,624 doses of Sinovac vaccine for health workers in the city. Bandar Lampung. ANTARA PHOTOS / Ardiansyah

    A vaccinator officer shows the COVID-19 vaccine produced by Sinovac which will be injected to a number of representatives of officials during the second phase of vaccination at the Bandar Lampung City Government Office, Lampung, Friday, January 29, 2021. The second stage of vaccination in Bandar Lampung is targeted at 9,624 doses of Sinovac vaccine for health workers in the city. Bandar Lampung. ANTARA PHOTOS / Ardiansyah

    TEMPO.CO, Jakarta - Commission IX House of Representatives (DPR) legislator, Rahmad Handoyo, on Tuesday had asked members of the public to not be concerned about the rather low efficacy of Sinovac vaccines.

    He argues that the efficacy rate - despite confirmation from a Chinese official - is still above the minimum threshold set by the World Health Organization (WHO) on vaccine efficacy. 

    “We don’t need to worry about the honest statement from the Chinese Official. The threshold set by WHO is 50 percent and I believe the Chinese production is above that so there is nothing to worry about,” said the legislator from the PDIP party.

    In an attempt to downplay talks about the low efficacy rate of Sinovac vaccines, he said that Covid-19 vaccines are a rare commodity in the global scale as many countries need them and that he is grateful that healthcare workers in Indonesia have been vaccinated. 

    “That is the standard set by the WHO. Once again don’t be taken away by a piece of information,” said the legislator who further defended the use of Sinovac by stating that it has no issue in terms of safety.

    Read: Indonesia to Receive 10 Million Doses of Sinovac Vaccine This April

    ANTARA